Kaplan Fox is Investigating Whether Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Made Misleading Statements to Investors
Alpha Vantage · The National Law Review · · AI-summarised by FinFlash
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following the discontinuation of its pociredir program for sickle cell disease. This decision came after the FDA expressed heightened concerns about the drug's benefit-risk profile due to malignancy risks associated with PRC2 inhibitors, leading to a significant drop in Fulcrum Therapeutics' stock price. The law firm is seeking investors who suffered losses to join their investigation.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.